Lunai Bioworks Inc. reported financial results for the fiscal year ended June 30, 2025. The company, which operates through subsidiaries including Renovaro Biosciences, Renovaro Cube, and BioSymetrics Inc., reported a net loss of $178.01 million for the year, compared to a net loss of $88.43 million in the prior year. This represents an increase in net loss of $89.58 million, or 101% year-over-year. The company remains pre-revenue and has not generated any sales revenue to date. Lunai Bioworks stated that it does not anticipate earning revenues until its therapies or products are approved for marketing and sale. Comprehensive loss for the year was reported at $167.02 million, compared to a comprehensive loss of $88.57 million in the previous fiscal year, reflecting an increase of $78.46 million, or 89%. A significant recent development includes the bankruptcy of Gedi Cube B.V., an indirect subsidiary of Lunai Bioworks. Gedi Cube B.V. filed for bankruptcy in September 2025 due to its inability to meet payments as they became due. The company determined that a material impairment of Gedi Cube B.V. had occurred as a result. Lunai Bioworks indicated that funding expected during fiscal 2026 will be allocated to satisfy existing and future obligations and liabilities, support commercialization efforts, conduct clinical and regulatory work for product candidates, and begin building working capital reserves.